Tolerability and Efficacy of Apixaban Versus Rivaroxaban for Non- Valvular Atrial Fibrillation | [Medical Forum • 2022]

Author(s):

1. Mahboob Ur Rehman: Department of Cardiology, Pakistan Institute of Medical Sciences Islamabad.Pakistan

2. Fazlul Aziz Mian: Department of Cardiology, Pakistan Institute of Medical Sciences Islamabad.Pakistan

3. Farhan Faisal: Department of Cardiology, Pakistan Institute of Medical Sciences Islamabad.Pakistan

4. Anwar Ali: Department of Cardiology, Kulsum International Hospital, Islamabad.Paksitan

5. Amjad Abrar: Department of Cardiology, Kulsum International Hospital, Islamabad.Paksitan

6. Ali Raza: Department of Cardiology, Pakistan Institute of Medical Sciences Islamabad.Pakistan

Abstract:

The main objective of the study is to find the tolerability and efficacy of apixaban Vs rivaroxaban for non-vulvular atrial fibrillation Study Design: Cross-sectional study Place and Duration of Study: This study was conducted at the Pakistan Institute of Medical Sciences Islamabad during August 2020 to July 2021 for a period of ten months. Materials and Methods: Bunch I patients will be given rivaroxaban 15mg everyday two times per day for one month then 20mg day to day for quite some time and Group II patients will be given 5mg two times day to day all through the treatment period. Results: The information was gathered from 120 patients. Out of 120 members, 60 were treated with rivaroxaban, while 60 were treated with Apixaban. Middle age was 26 years in the gathering I and 25.3 years in the gathering II (p=0.705). Female cases counted for 41 (86%) and 19 (14%) in I and II gatherings, individually. Conclusion: It is reasoned that oral anticoagulant drugs for counteraction of stroke in non-valvular AF have been developed and adding new choices and benefits for patients and doctors like less recurrence of medication and food associations, no requirement for checking, expansive helpful list and endured better by patients.

Page(s): 100-103

DOI: DOI not available

Published: Journal: Medical Forum, Volume: 33, Issue: 3, Year: 2022

Keywords:

Tolerability , Apixaban , rivaroxaban , NonValvular Atrial Fibrillation

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views